Alvotech tekur þátt í heilbrigðisráðstefnu fjárfestingabankans Jefferies í New York dagana 5.-6. júní 2024
29 mai 2024 08h04 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tekur í heilbrigðisráðstefnu Jefferies fjárfestingabankans, í New York dagana 5.-6. júni nk. Alvotech mun halda kynningu og funda með fjárfestum og viðskiptavinum á...
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
29 mai 2024 08h04 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
21 mai 2024 17h15 HE
|
Alvotech
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period...
Alvotech birtir uppgjör fyrir fyrsta ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
21 mai 2024 17h14 HE
|
Alvotech
Heildartekjur á fyrsta ársfjórðungi 2024 jukust í 37 milljónir dollara, úr 16 milljónum dollara á sama tímabili í fyrraFramlegð á fyrsta fjórðungi 2024 var 17 milljónir dala, sem er 40 milljóna...
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
21 mai 2024 17h14 HE
|
Alvotech
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last yearGross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last...
Alvotech gengur til samstarfs við Dr. Reddy‘s um markaðssetningu AVT03, fyrirhugaðrar hliðstæðu við Prolia og Xgeva, í Bandaríkjunum og Evrópu
21 mai 2024 08h01 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gert samstarfssamning við Dr. Reddy’s Laboratories SA, dótturfyrirtæki Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) um sölu- og...
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
21 mai 2024 08h01 HE
|
Alvotech
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)Alvotech will be responsible for development and...
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
21 mai 2024 08h00 HE
|
Alvotech
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and...
Alvotech og Teva Pharmaceuticals hefja sölu á líftæknilyfjahliðstæðunni Simlandi í Bandaríkjunum
20 mai 2024 20h25 HE
|
Alvotech
Simlandi er fyrsta líftæknilyfjahliðstæðan í háum styrk með útskiptanleika við Humira á markaði í Bandaríkjunum Alvotech (NASDAQ: ALVO) og samstarfsaðili þess Teva Pharmaceuticals Ltd. tilkynntu í...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
20 mai 2024 20h25 HE
|
Alvotech
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical...